Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Staar Seeking Expedited Approval For Aqua-Flow Glaucoma Drainage Device

This article was originally published in The Gray Sheet

Executive Summary

Anticipated expedited review and subsequent FDA approval of Staar Surgical's Aqua-Flow collagen glaucoma drainage device would make it available for U.S. launch by the end of the year or early 2001, the firm projected during a March 30 teleconference.

You may also be interested in...

Staar Surgical

Financial restructuring plan will involve one-time charges of $15-17 mil. in the second quarter, the firm says. Included are the "write-off or restructuring of under-performing subsidiaries, write-off of old or unnecessary patents and write-off of inventory which the company believes may become obsolete or does not fit the future strategy," as well as a write-off of investments in the Japanese Canon/Staar joint venture and laser centers. Combined with additional cost savings measures, the changes will result in annual savings of $0.32 to $0.45 per share, Staar says. However, added costs of up to $1.5 mil., or $0.10 per share, are expected to prepare for marketing of the Aqua-Flow collagen glaucoma drainage device, for which FDA approval is anticipated in the first quarter of 2001 (1"The Gray Sheet" April 3, p. 20). First-quarter 2000 results announced May 11 included a 4.7% decline in sales to $14.1 mil. Net income was $271,000 compared to $673,000 for the first quarter last year. "The board of directors and management goal is to be a $250 mil. company within the next three to five years," commented chief operating officer William Huddleston

Bristol/Exelixis Detail Survival Benefit For Opdivo/Cabometyx In Renal Cancer

Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts